scientific programme
34
tuesday, 24 June 2014
KS-01-003
Cortical thinning and disrupted structural
connectivity in medial prefrontal region as-
sociated with theory of mind and social func-
tioning in first-episode psychosis
Tae Young Lee, Republic of Korea
J. S. Kwon, W. H. Jung, J. W. Hur, J.-Y. Yun,
S. N. Kim, J. H. Jang, D.-H. Kang
KS-01-004
Neurocognitive components of social impair-
ments in schizophrenia
Sohee Park, USA
K. Thakkar
Learning Objectives:
In this symposium cur-
rent findings on how changes in the brain can
impact on poor social functions, a major im-
pairment in schizophrenia.
EW-05
EDUCATIONAL WORKSHOP
10:00–11:00
Room 13
Understanding modern genetics
Chair: Dan Rujescu, Germany
EW-05-001
Genetic prediction of antipsychotic response
and side effects
James Kennedy, Canada
A. Tiwari, D. Taylor, C. Zai, J. Pouget, N. Chowd-
hury, J. Lieberman, H. Meltzer, D. Mueller
EW-05-002
Pharmacogenetics: Using genetic informa-
tion to enhance treatment
Anil Malhotra, USA
Learning Objectives:
This workshop will
discuss advances in predicting antipsychotic
response and side effects as well as ways to
enhance treatment based on an individuals
genetic make up.
EW-06
EDUCATIONAL WORKSHOP
11:10–12:10
Room 13
Treatment guidelines for substance abuse
comorbidity
Chair:
Michael Krausz, Canada
EW-06-001
Treatment beyond guidelines
David Nutt, United Kingdom
EW-06-002
Harm reduction in the multidisciplinary
guidelines for alcohol and opiate depen-
dence in the Netherlands
Wim van den Brink, The Netherlands
Learning Objectives:
Those attending this
workshop will be updated on the best way to
manage problems faced by those suffering
from treatment abuse.
PL-04
PLENARY LECTURE
14:00–14:45
Plenary Hall A
Track: Discovery research
Topic: Neurodegenerative disorders, incl.
Parkinson‘s Disease; Alzheimer‘s Disease;
Huntington‘s Disease; Fronto-Temporal De-
mentia; Vascular Dementia (A)
Brain science using iPS cell technology
non-human primates
Hideyuki Okano, Japan
Learning Objectives:
Delegates attending
this presentation will gain knowledge on the
progress being made in using stem cells as
a treatment for disorders of the central ner-
vous system.
S-16
SYMPOSIUM
15:00–17:00
Ballroom A
Track: Translational
Topic: Depression (A)
New basic and clinical developments for
treatment resistant depression
Chair:
Alan Frazer, USA
Co-Chair: Siegfried Kasper, Austria
S-16-001
Drug development in treatment-resistant
depression: Current progress, major hurdles
and future strategies
Carlos Zarate, USA
S-16-002
TRD: Results of a European multi-centre
study
Siegfried Kasper, Austria
S-16-003
Potential of mGlu2/3 receptor antagonists for
treatment-resistant depression: An alterna-
tive to ketamine
Shigeyuki Chaki, Japan
S-16-004
Neurochemical and behavioral effects of
vagal nerve stimulation
Alan Frazer, USA
A. Shah, F. Carreno
